VitriVax Secures $87 Million Series C Funding to Advance Lyme Disease Vaccine Candidate into Clinical Development and Expand Pipeline

VitriVax Raises $87 Million in Oversubscribed Series C Financing to Advance Lyme Disease Vaccine and Expand ALTA® Technology Pipeline VitriVax, a vaccine development and formulation technology company, has announced the…

Read MoreVitriVax Secures $87 Million Series C Funding to Advance Lyme Disease Vaccine Candidate into Clinical Development and Expand Pipeline

Instem and Synopsys Partner to Enhance Extractables and Leachables Risk Assessment Through Leadscope and CertiSim Integration

Instem Joins Ansys Technology Partner Program to Integrate Leadscope With CertiSim for Advanced Packaging Toxicology and Safety Assessment Instem, a leading provider of software solutions for life sciences research and…

Read MoreInstem and Synopsys Partner to Enhance Extractables and Leachables Risk Assessment Through Leadscope and CertiSim Integration

Bristol Myers Squibb Reports First Phase 3 Clinical Results from ADEPT Program Evaluating KarXT for Alzheimer’s Disease-Related Psychosis

Bristol Myers Squibb Reports Preliminary Phase 3 ADEPT Study Results Showing Improvements in Alzheimer’s Disease-Related Psychosis With KarXT Bristol Myers Squibb, a global biopharmaceutical company focused on developing innovative medicines…

Read MoreBristol Myers Squibb Reports First Phase 3 Clinical Results from ADEPT Program Evaluating KarXT for Alzheimer’s Disease-Related Psychosis